Biotech Values

[jq1234]

I am not surprised you drew your conclusion because the article isn't well written. This type of article misleads the general public.

The drug incudes low dose of dextromethorphan hydrobromide (20 mg), cough supressant, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations, which have been on the market for years if not decades.

FDA turned down original 30/30mg. AVNR did new study with 30/10mg, 20/10mg. This time, FDA approved only 20/10mg for ALS and MS. The label is pretty restrictive. I do question the market potential.

Here is a better article from Bloomberg:

http://www.businessweek.com/news/2010-10-29/avanir-drug-cleared-for-uncontrolled-laughing-crying.html